|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Integrated Screen, Part 1 (NY)
Test Code16976
CPT Codes
Refer to Maternal Serum Integrated Screen, Part 2(NY) (test code 16977)<br /> **This code is for New York patient testing. For Non-New York State patient testing, use Test Code 16148**
Includes
*PAPP-A
This test will be reported and billed with Maternal Serum Integrated Screen, Part 2 results.
This test will be reported and billed with Maternal Serum Integrated Screen, Part 2 results.
Preferred Specimen
1.5 mL serum
Minimum Volume
0.8 mL
Instructions
Perform test between 9.0 weeks and 13.9 weeks gestational age.
A special Maternal Serum Screen requisition, designed to obtain patient data and the patient's informed consent, must be used when ordering this test, because these results are influenced by certain patient characteristics. All data requested on the requisition form must be complete to permit accurate interpretation of results.
A special Maternal Serum Screen requisition, designed to obtain patient data and the patient's informed consent, must be used when ordering this test, because these results are influenced by certain patient characteristics. All data requested on the requisition form must be complete to permit accurate interpretation of results.
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days
Refrigerated: 14 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Moderate to gross hemolysis • Lipemia
Methodology
Chemiluminescence (CL) • Immunoassay (IA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon-Sat a.m.; Report available: 4-6 days
Limitations
Maternal age confirmation and number of fetuses may alter result interpretation. Maternal screening tests consistent with increased risk of trisomy should be confirmed with CVS or amniotic fluid specimen. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.
Reference Range
See Laboratory Report
Clinical Significance
To assess maternal risk for carrying a fetus with Down Syndrome (Trisomy 21), Trisomy 18, or a neural tube defect. These types of tests are standard-of-care in obstetrics.
